Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa rollover study in lung cancer
NCT05061823Phase 3Completed
- Sponsor
- EMD Serono
- Start
- Dec 2021
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 3 trial of bintrafusp alfa in lung cancer, cancer, sponsored by EMD Serono. Started Dec 2021; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
lung cancercancer
Beyond the preview
Go deeper on NCT05061823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061823.